The BBRC hosts a European symposium on the latest technologies in biomarkers

The BBRC hosted yesterday a mini European symposium organized by Quanterix, in collaboration with the Barcelonaβeta Brain Research Center (BBRC), and dedicated to Simoa technology and the advances it enables in research on Alzheimer's disease. The event, in which more than 30 people participated physically, took place at the BBRC facilities at the Pasqual Maragall Foundation, and could also be followed online.

The participants learned first-hand about the new Fluid Biomarkers and Translational Neurology laboratory at the BBRC, one of the reference platforms with access to this technology that allows biomarkers to be detected more precisely. The teams in charge of identifying and studying new blood biomarkers in neurodegenerative diseases at the BBRC are led by Dr. Marc Suárez-Calvet, head of the Fluid Biomarkers and Translational Neurology Group, and Dr. Marta del Campo, Director of the Fluid Biomarkers Platform.

After the opening of the conference by Dr. Paula Perin from Quanterix, Dr. Marc Suárez-Calvet intervened, with a talk focused on blood biomarkers of preclinical Alzheimer's. The second intervention was given by Dr. Olivia Belbin, a researcher at the Hospital de la Santa Creu i Sant Pau, with a presentation on biomarkers in plasma for Alzheimer's disease associated with Down syndrome. The day ended with a visit to this new leading laboratory in our country.